Sino-US Oncotherapy Translational Medicine International Sci-Tech Cooperation Demonstration Base is mainly engaged in tumor biological treatment cooperation research by relying on cancer treatment advantage of Cancer Center of Dalian Medical University and University of California, and is the Oncotherapy Translational Medicine International Sci-Tech Cooperation Demonstration Base initially established in China.
Opening of Demonstration Base
In the ceremony, party secretary Sun Zhaolin awarded the 1st Huatuo Prize for International Oncotherapy Contributions for American cooperative expert professor Dennis J. Slamon. Professor Dennis J. Slamon is the director of Clinical/Translational Research Center of Jonson Comprehensive Cancer Center, UCLA, the discoverer of targeted drug protein HER2 for breast cancer, and the founder of the first international breast cancer targeted drug “Herceptin”. He was awarded the 1st Huatuo Prize for International Oncotherapy Contributions with his outstanding contribution in the biological treatment of breast cancer. Subsequently, professor Dennis J. Slamon gave an academic report on CDK4/6 inhibitor small molecular targeted drugs as approved by FDA lately, diagnostic treatment and prognosis relations of patients with breast cancer.
Sun Zhaolin awarded the prize for professor Dennis J. Slamon